TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events Related to ADVM-043
Endpoint domain: Adverse events/effects
Primary endpoint: Area-under-the-concentration-time-curve (AUC) of bafetinib in dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak concentration (Cmax) of bafetinib in dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of bafetinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of bafetinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monolateral index for each adrenal gland
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Aldosterone/cortisol index for each adrenal gland
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in levels of Imatinib in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of cytokines in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-inferiority of indocyanine green guided sentinel lymph node biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Topographic analysis post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: airway obstruction evaluated by NOSE scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thoroughness of Invasive Staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stage-Appropriateness Treatment Selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Response rate (30% decrease in PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative EEG Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in 3-PBA Levels in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Difference in Median 3-PBA Levels in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Difference in Median 6-CN Levels in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in ankle brachial indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes to quality of life surveys
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes to walking distance until symptoms of claudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of cecal intubation within 15 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent disease
Endpoint domain: Mortality/survival
Primary endpoint: Average Correlations Between Average Time Series - Left & Right Hemisphere of the Brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in Volume - Left & Right Habenula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of Correct No Button Presses During Functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transcranial Motor Evoked Potentials (TcMEP) Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraoperative propofol dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Clinical Response at Week 12 Who Also Had Clinical Response at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients achieving textbook outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Grades II-IV Acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage number of patients with hepatitis due to HBV reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage number of patients with hepatitis due to Safety assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Chemotherapy disruption due to hepatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of balloon pumps in the Balloon Analogue Risk Task after stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural activity during Balloon Analogue Risk Task after stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aggressive behavior after stimulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: First pass success without hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of outpatient clinics and emergency department use
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-efficacy level in diabetes management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reversible vasoconstriction on medical imaging of intracranial arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pathological Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients reaching the acceptability threshold
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Emergency Department Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Hospital Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mobility assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of alerts
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of secondary hypogonadism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall Objective Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With at Least 1 Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of MDV3100
Endpoint domain: Adverse events/effects
Primary endpoint: Discrimination of subtle lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Desmopressine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child cognitive at 4 months of age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Child cognitive at 6 months of age
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Peak hour patient activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MACE survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Newly Initiating Febuxostat Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Established Cardiovascular Disease (CVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: flow mediated dilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alcohol Use Behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of device related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Acute Pain Relief response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability evaluation
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in long-term physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary artery/graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Limb Salvage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptoms of lower extremity Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pentraxin-3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decisional conflict scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decision regret scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of correctly answered questions assessing knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: probing depth of peri-implantitis sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of symptomatic recurrent venous thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients With Serious Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to healing of target ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Increase in Oral Body Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of Rescue Medication
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodynamic severity (Percentage of stenosis properly classified by iFR®)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of tramadol and its metabolites in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain as Measured by Numerical Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Joint Loading: First Peak Knee Adduction Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Outgrowth from wheat allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Targeted science content outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Metabolite changes in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: complete disappearance of the BCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Breathlessness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in Psoriasis Area and Severity Index (PASI) at Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced at Least One Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life Questionnaire - Bronchiectasis (QoL B) Respiratory Symptoms domain score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sputum culture conversion (SCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of BIBF 1120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and intensity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: DIC resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hepatotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: mucosal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: neurologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: CD34+ cell count peak level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pinch Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional MRI BOLD Signal From Motor Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DMFT index (Decayed, Missing, Filled, Tooth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPI (Community Periodontal Index) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TDI (Dental Trauma Index) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TF (Thylstrup & Fejerskov Index for dental Fluorosis) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain functional magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MELD Score Mean(SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Serious Adverse Events (SAEs) During the Treatment Phase
Endpoint domain: Adverse events/effects
Primary endpoint: MELD Score Change From Baseline Mean(SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Not Bothered at All by Halos
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changing in height of the elevated zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: New bone-to-implant contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major & minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Port of entry related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC) of tasimelteon with CYP3A4 inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of tasimelteon with CYP3A4 inducer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Blood glucose response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: numbers of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: number of local site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve from serial budesonide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metrics of eye movement for concussion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients with Graves disease in ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge about breast cancer prevention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Communication about breast cancer prevention
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Distrust of medical research
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Quality Of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reductions in depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reductions in AOD use
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of delayed gastric emptying syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disease-control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery by Cesarean Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: FVIII Inhibitor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Regional N-acetyl aspartate (NAA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total and regional gray matter volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate in reaching within working distance of the Cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mammogram test receipt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of nocturnal gonadotropin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Satisfaction of patient, parent, and consumer advocate co-investigators
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants who completed the 24 weeks of the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of target sample size enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stem anteversion of the hip radiograph
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stem anteversion of the CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein (CRP) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory-related changes in brain electrical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma drug and drug metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Environmental contamination with C. difficile spores
Endpoint domain: Adverse events/effects
Primary endpoint: Skin contamination with C. difficile spores
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Any New Onset of Autoimmune Diseases (NOADs) and Other Immune Mediated Inflammatory Disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Hematological and Biochemical Parameters With Respect to Normal Laboratory Ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Event of Death, Graft Loss or Rejection
Endpoint domain: Mortality/survival
Primary endpoint: Changes in hyperoxic chemoreflex sensitivity (CHRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow mediated endothelial vasodilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC0-∞ of Eculizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dynamic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in urinary albumin:creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Executive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: AUC0-τ,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T½
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With DAS28 Remission Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline at Week 16 in Attention Questionnaire Scores (AQS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline at Week 16 in Burden Interview (BI) Scores
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: FEV1 peak0-3 Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Renal remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with relevant side effects
Endpoint domain: Adverse events/effects
Primary endpoint: NF-kappa B binding activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy to Predict Acute Kidney Injury (AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes